Johnson & Johnson
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joaquin Duato
- Full Time Employees
- 138,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Johnson & Johnson Plaza New Brunswick NJ United States of America 08933
- IPO Date
- Jan 2, 1943
- CIK
- 0000200406
- Website
- jnj.com
- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
How to Build $3,000 a Month in Dividend Income to Cover the Average Social Security Check
Playing It Safe at 63 With $850,000 in Cash and Bonds Is Quietly Costing This Retiree About $34,000 a Year
Health Care ETFs: XLV Delivers Low Fees and Solid Returns
The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer
64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends
This $1.7 Million Portfolio Pays More Than a Member of Congress
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
How to Build $3,000 a Month in Dividend Income Before You Turn 50
What a $2 Million Dividend Portfolio Actually Pays a New York Retiree After Taxes
A $750,000 Portfolio That Quietly Pays You More Than the Average Social Security Check
A $650,000 Portfolio That Could Send You to the Super Bowl Every Year
New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.
How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)
The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar
The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I'm Loading Up on Anyway
3 No-Brainer Dividend Growth Stocks to Buy in June